
    
      The drug being tested in this study is called darvadstrocel (Cx601). Darvadstrocel is being
      tested to treat people who have Crohn's disease (CD) and complex perianal fistula. This study
      will look at the long-term safety and efficacy of darvadstrocel in the treatment of complex
      perianal fistula in CD.

      The study will enroll approximately 150 patients. Participants who received darvadstrocel or
      placebo in study ADMIRE-CD II (Cx601-0303, NCT03279081) and who have completed the 52 weeks
      of the study will be enrolled in this long-term extension study.

      This multi-center trial will be conducted worldwide. The overall time to participate in this
      study is 104 weeks. Participants will make multiple visits to the clinic and will be
      contacted by telephone every 3 months for a follow-up assessment.
    
  